Table 3.
Effects of single-pill amlodipine/atorvastatin-based therapy on glucose-lipid metabolism and inflammatory and oxidative stress markers.
| Baseline | Week 16 | |
|---|---|---|
| Glucose-lipid metabolism | ||
| Fasting plasma glucose (mg/dL) |
130 ± 51 | 127 ± 56 |
| Glycated hemoglobin (%) | 6.1 ± 0.8 | 6.2 ± 0.9 |
| Total cholesterol (mg/dL) | 230 ± 33 | 180 ± 37** |
| LDL-cholesterol (mg/dL) | 143 ± 27 | 97 ± 30** |
| HDL-cholesterol (mg/dL) | 63 ± 21 | 61 ± 19 |
| Triglycerides (mg/dL) | 195 ± 140 | 180 ± 134 |
| Inflammatory and oxidative stress markers | ||
| hs-CRP (mg/dL) | 0.18 ± 0.24 | 0.09 ± 0.10 |
| Serum pentosidine (μg/mL) | 0.036 ± 0.013 | 0.046 ± 0.018** |
Values are means ± SD. CRP: C-reactive protein. **P < 0.01.